UNCY
Unicycive Therapeutics, Inc.
$5.73
+0.45 (+8.52%)
At close · Jul 2
Market Cap
$152.99M
Shares
26,700,027
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Valuation over time computed as of each quarter's filing date
Chart builder compare any reported metrics over time
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| — | — | — | $675K | $951K | — | — | |
| $8.56M | $9.12M | $20.01M | $12.9M | $12.44M | $6.08M | $1.02M | |
| $21.41M | $20.4M | $12.1M | $8.55M | $6.57M | $2.9M | $1.01M | |
| $701K | — | — | — | $383K | $245K | $58K | |
| — | — | — | — | $428K | $468K | — | |
| $29.97M | $29.52M | $32.12M | $21.45M | $19M | $8.98M | $2.02M | |
| -$29.97M | -$29.52M | -$32.12M | -$20.77M | -$18.05M | -$8.98M | -$2.02M | |
| Operating Margin | — | — | — | -3077.63% | -1898.21% | — | — |
| EBITDA | — | — | — | — | -$17.62M | -$8.51M | — |
| — | $71K | $71K | $82K | $6000 | $628K | $244K | |
| $1.18M | $1.01M | $1.26M | $615K | — | — | — | |
| -$9.98M | $2.96M | -$4.61M | -$9.77M | -$6000 | -$1.04M | -$244K | |
| -$39.95M | -$26.56M | -$36.73M | -$30.54M | -$18.06M | -$10.02M | -$2.26M | |
| Net Margin | — | — | — | -4525.04% | -1898.84% | — | — |
| -$39.89M | -$26.56M | -$37.82M | -$31.41M | -$18.06M | -$10.02M | — | |
| — | -$26.56M | -$36.73M | — | — | — | — | |
| USD/shares | — | $-1.67 | $-5.65 | $-1.28 | $-1.20 | $-0.86 | $-0.27 |
| USD/shares | — | $-1.67 | $-5.65 | $-1.28 | $-1.20 | $-0.86 | — |
| shares | — | 15.89M | 6.7M | 24.54M | 15.06M | 11.68M | 8.5M |
| shares | — | 15.89M | 6.7M | 24.54M | 15.06M | 11.68M | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.